Fenwick represented Scribe Therapeutics Inc., a company focused on engineering the most advanced platform for CRISPR-based genetic medicine, in its research collaboration with Biogen Inc. (NASDAQ: BIIB) to develop and commercialize CRISPR-based therapies that address an underlying genetic cause of Amyotrophic Lateral Sclerosis (ALS).

Under the terms of the collaboration, Scribe will work with Biogen to create therapeutics for genetically-driven ALS, with an option to pursue an additional neurological disease target with high, unmet need. Scribe will receive $15 million upfront and is eligible for more than $400 million in potential development and commercial milestone payments between the two targets of interest. Scribe is also eligible to receive tiered, high single digit to sub-teen royalties.

More information about the collaboration can be obtained from Scribe’s announcement.

The Fenwick transaction team included life sciences partner Stefano Quintini and counsel Claire O’Callaghan.

Login

Don’t have an account yet?

Register